Hodgkin lymphoma - clinical
Thierry Leblanc, Paul Harker-Murray, Christine Mauz-Körholz, Maurizio Mascarin, et al.
Conclusion: Response-adapted tx with nivolumab + BV achieved high CMR rates in primary refractory pts with cHL after 4 cycles of induction. In pediatric pts with a standard risk of relapse, induction with nivolumab + BV, followed by BV + bendamustine intensification for suboptimal response, demonstrated high CMR rates and a favorable safety profile prior to consolidation.
Andrea Gallamini, David Straus, Monika Dlugosz-Danecka, Sergey Alekseev, et al.
Conclusion: Follow-up at 3 years demonstrates that frontline treatment of stage 3/4 cHL with A+AVD provides a durable treatment benefit compared with ABVD that is independent of PET2 status. While direct comparisons cannot be made, efficacy with A+AVD appears favorable in the context of findings with PET-adapted strategies, without requiring interim PET assessment, escalation of therapy, or bleomycin.
Eva Domingo-Domènech, Radhakrishnan Ramchandren, Antonio Rueda, Marek Trněný, et al.
Conclusion: With extended follow-up, nivolumab followed by N-AVD demonstrated a 21-month PFS rate of 83% per investigator, a high metabolic response rate with 75% CMR at EOT per IRC, with no new safety signals. Incorporation of Deauville assessment improved the concordance of CR between IRC- and investigator-assessed responses. Nivolumab followed by N-AVD provides a promising alternative treatment option in newly diagnosed advanced-stage cHL.
Michael Fuchs, Helen Goergen, Carsten Kobe, Hans Eich, et al.
Conclusion: In early-stage favorable HL, a positive PET after 2xABVD is associated with a larger tumor volume and represents a risk factor for PFS among patients treated with standard CMT, particularly when DS4 is considered as cutoff for positivity. PET-guided treatment intensification in this high-risk subgroup might help to reduce the frequency of relapses.
Hidde L.A. Posthuma, Josée M. Zijlstra, Otto Visser, Pieternella J. Lugtenburg, et al.
Conclusion: In this large, nationwide population-based study, survival among various subgroups of patients with NLPHL during a 23-year period was largely comparable to the survival of the general population. Further, we noted no improved survival after the introduction of rituximab into the therapeutic arsenal of NLPHL since 2003. Future prospective studies in NLPHL are necessary to establish evidence-based treatment recommendations that consider the delicate balance between efficacy, toxicity, and quality of life.